Genetic Variants Associated with Methotrexate Efficacy and Toxicity in Early Rheumatoid Arthritis: Results from the Treatment of Early Aggressive Rheumatoid Arthritis Trial

Methotrexate (MTX) has emerged as first-line therapy for early moderate to severe rheumatoid arthritis (RA), but individual variation in treatment response remains unexplained. We tested the associations between 863 known pharmacogenetic variants and MTX response in 471 TEAR Trial participants with...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Aslibekyan, Stella, Brown, Elizabeth E., Reynolds, Richard J., Redden, David T., Morgan, Sarah, Baggott, Joseph, Sha, Jin, Moreland, Larry W., O’Dell, James R., Curtis, Jeffrey R., Mikuls, Ted R., Bridges, S. Louis, Arnett, Donna K.
Formato: Artigo
Idioma:Inglês
Publicado: 2013
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3701736/
https://ncbi.nlm.nih.gov/pubmed/23545897
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/tpj.2013.11
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares